Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients

The objective of this study was to evaluate the antiretroviral efficacy and safety of ritonavir (600 mg twice a day [b.i.d.])-saquinavir (400 mg b.i.d.) compared to ritonavir (600 mg b.i.d.) in patients pretreated and receiving continued treatment with two nucleoside analogs. The study was placebo c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Michelet, Christian, Ruffault, Annick, Sébille, Véronique, Arvieux, Cedric, Jaccard, Philippe, Raffi, François, Bazin, Claude, Chapplain, Jean-Marc, Chauvin, Jean-Pierre, Dohin, Elisabeth, Cartier, François, Bellissant, Eric
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2001
Aiheet:
Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC90843/
https://ncbi.nlm.nih.gov/pubmed/11709314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.12.3393-3402.2001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia